Business Context and Reporting Period
This Form 8-K Current Report from LENZ Therapeutics, Inc. covers events occurring on June 30, 2026. The filing addresses corporate governance changes, specifically the departure of a director and subsequent committee appointments.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: Zach Scheiner resigned from the Board of Directors and all associated committees effective immediately on June 30, 2026.
- Board Size Reduction: The Board size was decreased to six (6) members following the resignation.
- Committee Appointment: Jeff George was appointed to the Audit Committee effective June 30, 2026.
- Audit Committee Composition: The current members are Shelley Thunen, Frederic Guerard, and Jeff George.
Guidance, Outlook, and Risks
The filing states that Dr. Scheiner's resignation was not the result of any dispute or disagreement regarding the Company's operations, policies, or practices. No financial guidance, outlook, or new risk factors were disclosed in this report.
Key Facts for Investor Verification
- Confirm the current composition of the Board of Directors and Audit Committee.
- Verify that the resignation of Zach Scheiner was amicable and unrelated to operational disputes.
- Check for any subsequent filings regarding the appointment of a new director to replace the vacancy left by Dr. Scheiner.